Medigene AG reports Financial Results and Business Update for Q1 2024
April 26, 2024 03:00 ET
|
Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
April 25, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
April 24, 2024 07:00 ET
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Medigene to Present at Upcoming Scientific Conferences
April 17, 2024 06:00 ET
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
April 08, 2024 02:00 ET
|
Medigene AG
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Secures European Patent for its iM-TCR Technology
April 04, 2024 05:00 ET
|
Medigene AG
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
March 28, 2024 02:30 ET
|
Medigene AG
Significant corporate and scientific progress in 2023Innovations to End-to-End Platform technologies and IP portfolioPipeline additions with multiple KRAS neoantigen targetsAdvancement of lead program...
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 19, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG to report full year 2023 financial results on March 28, 2024
March 18, 2024 10:00 ET
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will...
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
March 13, 2024 06:00 ET
|
AKAMPION
The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy Advisors have previously collaborated with...